GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (NAS:NVCR) » Definitions » Cyclically Adjusted PB Ratio

NVCR (NovoCure) Cyclically Adjusted PB Ratio : 5.62 (As of Jul. 06, 2025)


View and export this data going back to 2015. Start your Free Trial

What is NovoCure Cyclically Adjusted PB Ratio?

As of today (2025-07-06), NovoCure's current share price is $17.71. NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $3.15. NovoCure's Cyclically Adjusted PB Ratio for today is 5.62.

The historical rank and industry rank for NovoCure's Cyclically Adjusted PB Ratio or its related term are showing as below:

NVCR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.02   Med: 5.9   Max: 10.92
Current: 5.63

During the past years, NovoCure's highest Cyclically Adjusted PB Ratio was 10.92. The lowest was 4.02. And the median was 5.90.

NVCR's Cyclically Adjusted PB Ratio is ranked worse than
82.13% of 498 companies
in the Medical Devices & Instruments industry
Industry Median: 1.88 vs NVCR: 5.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NovoCure's adjusted book value per share data for the three months ended in Mar. 2025 was $3.247. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.15 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


NovoCure Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NovoCure's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Cyclically Adjusted PB Ratio Chart

NovoCure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 9.60

NovoCure Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 5.64 5.11 9.60 5.66

Competitive Comparison of NovoCure's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted PB Ratio falls into.


;
;

NovoCure Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NovoCure's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=17.71/3.15
=5.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, NovoCure's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.247/134.9266*134.9266
=3.247

Current CPI (Mar. 2025) = 134.9266.

NovoCure Quarterly Data

Book Value per Share CPI Adj_Book
201506 1.745 100.684 2.338
201509 1.466 100.392 1.970
201512 2.994 99.792 4.048
201603 2.611 100.470 3.506
201606 2.176 101.688 2.887
201609 1.845 101.861 2.444
201612 1.635 101.863 2.166
201703 1.463 102.862 1.919
201706 1.326 103.349 1.731
201709 1.306 104.136 1.692
201712 1.269 104.011 1.646
201803 1.174 105.290 1.504
201806 1.212 106.317 1.538
201809 1.236 106.507 1.566
201812 1.204 105.998 1.533
201903 1.321 107.251 1.662
201906 1.624 108.070 2.028
201909 1.924 108.329 2.396
201912 2.188 108.420 2.723
202003 2.411 108.902 2.987
202006 2.651 108.767 3.289
202009 3.018 109.815 3.708
202012 4.657 109.897 5.718
202103 3.606 111.754 4.354
202106 3.833 114.631 4.512
202109 3.980 115.734 4.640
202112 3.948 117.630 4.529
202203 4.169 121.301 4.637
202206 4.217 125.017 4.551
202209 4.244 125.227 4.573
202212 4.200 125.222 4.526
202303 4.070 127.348 4.312
202306 3.899 128.729 4.087
202309 3.688 129.860 3.832
202312 3.385 129.419 3.529
202403 3.340 131.776 3.420
202406 3.349 132.554 3.409
202409 3.337 133.029 3.385
202412 3.319 133.157 3.363
202503 3.247 134.927 3.247

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NovoCure  (NAS:NVCR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NovoCure Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Executives
Frank X Leonard officer: President, CNS Cancers US 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Ashley Cordova officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Uri Weinberg officer: Chief Innovation Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Michal Nath Puri officer: Chief Human Resources Officer BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039
W Anthony Vernon director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, NEW YORK NY 10018
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Wilhelmus Cm Groenhuysen officer: Chief Financial Officer C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654
Pritesh Shah officer: Chief Commercial Officer C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Arye Barak Ben officer: General Counsel TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
Kristin Stafford director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
William Patrick Burke officer: Chief Human Resources Officer 195 COMMERCE WAY, PORTSMOUTH NH 03801
Allyson J Ocean director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Asaf Danziger director, officer: Chief Executive Officer 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302
Ely Benaim officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850